/
ADIL
$2.59+$0.03 (+1.17%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$5.6M
2M shares
52-week range
$1.31 – $18.90
7% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
11.63%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-1591.16
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $563 | $565 | $564 | $0 | $0 | $564 | $0 | $0 |
| Gross profit | −$563 | −$565 | −$564 | $0 | $0 | −$564 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $368.5K | $4.0M | $5.9M | $8.4M | $2.0M | $1.3M | $3.2M | $2.6M |
| Operating income | −$7.0M | −$8.2M | −$10.9M | −$19.3M | −$10.9M | −$6.9M | −$8.3M | −$7.8M |
| EBITDA | −$7.0M | −$8.6M | −$10.9M | −$17.7M | −$10.8M | −$7.0M | −$13.2M | −$8.0M |
| Net income | −$11.6M | −$8.6M | −$10.9M | −$19.4M | −$12.7M | −$7.0M | −$13.2M | −$8.0M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1527.50 | -545.00 | -544.75 | -653.00 | -299.50 | -136.00 | -17.75 | -11.93 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $46M | $-3.85 | $-3.85–$-3.85 | 1 |
| 2027 | $4M | $-1.53 | $-1.53–$-1.53 | 1 |
| 2028 | $47M | $-1.71 | $-1.71–$-1.71 | 1 |
| 2029 | $96M | $-1.88 | $-1.88–$-1.88 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$7.97
Price
$2.59
Implied upside
+208%
Peer comparison
Adial Pharmaceuticals, Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.
www.adial.com- Employees
- 6
- IPO / List date
- Jul 27, 2018
- HQ
- CHARLOTTESVILLE, VA
Held by traders on TradeandTell
No one on the platform currently holds ADIL.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ADIL as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-02-06 | 1-for-25reverse |
| 2023-08-07 | 1-for-25reverse |
Recent trades on TradeandTell
No one on the platform has traded ADIL yet.
